Defective homologous recombination DNA repair imposed by BRCA1 or BRCA2 gene deficiencies sensitizes cells to double strand break (DSB)-inducing DNA damaging agents like platinum derivates and anthracyclines. The formation of RAD51 IRIF is impaired in BRCA1 or BRCA2 defective cells and also in other genetic defects leading to HR deficiency. In current healthcare these anti-cancer agents e.g. platinum derivates are usually administered at late stage of advanced breast cancer from which only a sub
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Cancer Institute, department of Medical Oncology, Rotterdam.
Eligibility
Inclusion criteria
Inclusion criteria: • The site of the tumor should be amendable for biopsy. NB lung metastases (high risk of hematothorax) and bone metastases (not suitable for ex vivo test because calcifications interfere with experimental procedures) are excluded. • Age >18 years • WHO performance status 0 or 1 • Bilirubin 100 x 10e9/L • INR <1.5 • Written informed consent
Exclusion criteria
Exclusion criteria: Current therapeutically use of anti-coagulant (coumarin derivates, warfarin, heparin or low molecular weight heparin [LMWH]) whereby a short interruption of drug use is not allowed. LMWH if used for prophylaxis is allowed. • Any psychological condition potentially hampering compliance with the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the proportion of patients with a useful test result (Putest) will be considered as the primary end point | — |
Contacts
Public ContactA. Jager
Erasmus MC, Room 471
Outcome results
None listed